This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Faries MB , Thompson JF , Cochran AJ , Andtbacka RH , Mozzillo N , Zager JS , Jahkola T , Bowles TL , Testori A , Beitsch PD , Hoekstra HJ , Moncrieff M , Ingvar C , Wouters Mwjm , Sabel MS , Levine EA , Agnese D , Henderson M , Dummer R , Rossi CR , Neves RI , Trocha SD , Wright F , Byrd DR , Matter M , Hsueh E , MacKenzie-Ross A , Johnson DB , Terheyden P , Berger AC , Huston TL , Wayne JD , Smithers BM , Neuman HB , Schneebaum S , Gershenwald JE , Ariyan CE , Desai DC , Jacobs L , McMasters KM , Gesierich A , Hersey P , Bines SD , Kane JM , Barth RJ , McKinnon G , Farma JM , Schultz E , Vidal-Sicart S , Hoefer RA , Lewis JM , Scheri R , Kelley MC , Nieweg OE , Noyes RD , Hoon DSB , Wang HJ , Elashoff DA , Elashoff RM
Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
N Engl J Med. 2017 Jun 08;376(23) :2211-2222
PMID: 28591523 PMCID: PMC5548388 URL: https://www.ncbi.nlm.nih.gov/pubmed/28591523
AbstractBACKGROUND: Sentinel-lymph-node biopsy is associated with increased melanoma-specific survival (i.e., survival until death from melanoma) among patients with node-positive intermediate-thickness melanomas (1.2 to 3.5 mm). The value of completion lymph-node dissection for patients with sentinel-node metastases is not clear. METHODS: In an international trial, we randomly assigned patients with sentinel-node metastases detected by means of standard pathological assessment or a multimarker molecular assay to immediate completion lymph-node dissection (dissection group) or nodal observation with ultrasonography (observation group). The primary end point was melanoma-specific survival. Secondary end points included disease-free survival and the cumulative rate of nonsentinel-node metastasis. RESULTS: Immediate completion lymph-node dissection was not associated with increased melanoma-specific survival among 1934 patients with data that could be evaluated in an intention-to-treat analysis or among 1755 patients in the per-protocol analysis. In the per-protocol analysis, the mean (+/-SE) 3-year rate of melanoma-specific survival was similar in the dissection group and the observation group (86+/-1.3% and 86+/-1.2%, respectively; P=0.42 by the log-rank test) at a median follow-up of 43 months. The rate of disease-free survival was slightly higher in the dissection group than in the observation group (68+/-1.7% and 63+/-1.7%, respectively; P=0.05 by the log-rank test) at 3 years, based on an increased rate of disease control in the regional nodes at 3 years (92+/-1.0% vs. 77+/-1.5%; P<0.001 by the log-rank test); these results must be interpreted with caution. Nonsentinel-node metastases, identified in 11.5% of the patients in the dissection group, were a strong, independent prognostic factor for recurrence (hazard ratio, 1.78; P=0.005). Lymphedema was observed in 24.1% of the patients in the dissection group and in 6.3% of those in the observation group. CONCLUSIONS: Immediate completion lymph-node dissection increased the rate of regional disease control and provided prognostic information but did not increase melanoma-specific survival among patients with melanoma and sentinel-node metastases. (Funded by the National Cancer Institute and others; MSLT-II ClinicalTrials.gov number, NCT00297895 .).
Notes1533-4406 Faries, Mark B Thompson, John F Cochran, Alistair J Andtbacka, Robert H Mozzillo, Nicola Zager, Jonathan S Jahkola, Tiina Bowles, Tawnya L Testori, Alessandro Beitsch, Peter D Hoekstra, Harald J Moncrieff, Marc Ingvar, Christian Wouters, Michel W J M Sabel, Michael S Levine, Edward A Agnese, Doreen Henderson, Michael Dummer, Reinhard Rossi, Carlo R Neves, Rogerio I Trocha, Steven D Wright, Frances Byrd, David R Matter, Maurice Hsueh, Eddy MacKenzie-Ross, Alastair Johnson, Douglas B Terheyden, Patrick Berger, Adam C Huston, Tara L Wayne, Jeffrey D Smithers, B Mark Neuman, Heather B Schneebaum, Schlomo Gershenwald, Jeffrey E Ariyan, Charlotte E Desai, Darius C Jacobs, Lisa McMasters, Kelly M Gesierich, Anja Hersey, Peter Bines, Steven D Kane, John M Barth, Richard J McKinnon, Gregory Farma, Jeffrey M Schultz, Erwin Vidal-Sicart, Sergi Hoefer, Richard A Lewis, James M Scheri, Randall Kelley, Mark C Nieweg, Omgo E Noyes, R Dirk Hoon, Dave S B Wang, He-Jing Elashoff, David A Elashoff, Robert M R01 CA189163/CA/NCI NIH HHS/United States P01 CA029605/CA/NCI NIH HHS/United States Clinical Trial, Phase III Comparative Study Journal Article Multicenter Study Randomized Controlled Trial United States N Engl J Med. 2017 Jun 8;376(23):2211-2222. doi: 10.1056/NEJMoa1613210.